Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03973996 · ClinicalTrials.gov registry record · NA
Gut-level Antiinflammatory Activities of Green Tea in Metabolic Syndrome
A NA study of Inflammation and Metabolic Syndrome, sponsored by Ohio State University.
- Completed
- Registry status
- NA
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT03973996: Completed NA study of Inflammation and Metabolic Syndrome, sponsored by Ohio State University.
NCT03973996 is a NA study of Inflammation and Metabolic Syndrome that has completed, run by Ohio State University. The registered enrollment target is 46 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03973996, a NA study of Inflammation and Metabolic Syndrome, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates dietary green tea extract to improve gut health and inflammation in persons with metabolic syndrome and healthy adults. Participants will complete two phases of intervention in random order in which they will consume green tea extract or placebo for one month and then switch to the opposite treatment for an additional month.
Primary Outcome
Data are biomarker fasting concentrations.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Green Tea Extract
Study Locations (1)
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2021-03-01 |
| Phase | NA |
What the finished NCT03973996 record still lists
NCT03973996 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (84% lower).
The record links to 4 conditions, with Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03973996 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT03973996 about?
NCT03973996 is a clinical study titled "Gut-level Antiinflammatory Activities of Green Tea in Metabolic Syndrome". This study evaluates dietary green tea extract to improve gut health and inflammation in persons with metabolic syndrome and healthy adults. Participants will complete two phases of intervention in random order in which they will consume green tea extract or placebo for one month and then switch to ...
What is the current status of trial NCT03973996?
This trial is currently completed. It is a NA study. The enrollment target is 46 participants. The study started on 2019-07-01. Estimated completion is 2021-03-01.
What conditions does trial NCT03973996 study?
This clinical trial studies the following conditions: Inflammation, Metabolic Syndrome, Dysbiosis, Endotoxemia.
What interventions are being tested in trial NCT03973996?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Green Tea Extract (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03973996?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03973996 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03973996's enrollment target sits among peer trials
46 79th of 132 higher than 53 of 132 other Inflammation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Inflammation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
-
The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies
RECRUITING · NA
-
Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc
RECRUITING · NA
-
Evaluating Whether Hyperbaric Oxygen Therapy Can Improve VO₂-Max and Reduce Inflammation Markers in Healthy Adults Ages 30-60.
RECRUITING · NA
-
Impact of NMES and HPRO on Recovery After SAH- Pilot Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI